161 related articles for article (PubMed ID: 35447688)
1. N-1 Perfusion Platform Development Using a Capacitance Probe for Biomanufacturing.
Rittershaus ESC; Rehmann MS; Xu J; He Q; Hill C; Swanberg J; Borys MC; Li ZJ; Khetan A
Bioengineering (Basel); 2022 Mar; 9(4):. PubMed ID: 35447688
[TBL] [Abstract][Full Text] [Related]
2. Process intensification in fed-batch production bioreactors using non-perfusion seed cultures.
Yongky A; Xu J; Tian J; Oliveira C; Zhao J; McFarland K; Borys MC; Li ZJ
MAbs; 2019; 11(8):1502-1514. PubMed ID: 31379298
[TBL] [Abstract][Full Text] [Related]
3. Fed-batch performance profiles for mAb production using different intensified N - 1 seed strategies are CHO cell-line dependent.
Tang Y; Xu J; Xu M; Huang Z; Santos J; He Q; Borys M; Khetan A
Biotechnol Prog; 2024 Feb; ():e3446. PubMed ID: 38415506
[TBL] [Abstract][Full Text] [Related]
4. An automated high inoculation density fed-batch bioreactor, enabled through N-1 perfusion, accommodates clonal diversity and doubles titers.
Olin M; Wolnick N; Crittenden H; Quach A; Russell B; Hendrick S; Armstrong J; Webster T; Hadley B; Dickson M; Hodgkins J; Busa K; Connolly R; Downey B
Biotechnol Prog; 2024; 40(2):e3410. PubMed ID: 38013663
[TBL] [Abstract][Full Text] [Related]
5. Automation of high CHO cell density seed intensification via online control of the cell specific perfusion rate and its impact on the N-stage inoculum quality.
Schulze M; Lemke J; Pollard D; Wijffels RH; Matuszczyk J; Martens DE
J Biotechnol; 2021 Jul; 335():65-75. PubMed ID: 34090946
[TBL] [Abstract][Full Text] [Related]
6. Bioreactor productivity and media cost comparison for different intensified cell culture processes.
Xu S; Gavin J; Jiang R; Chen H
Biotechnol Prog; 2017 Jul; 33(4):867-878. PubMed ID: 27977910
[TBL] [Abstract][Full Text] [Related]
7. Development of a chemically defined platform fed-batch culture media for monoclonal antibody-producing CHO cell lines with optimized choline content.
Kuwae S; Miyakawa I; Doi T
Cytotechnology; 2018 Jun; 70(3):939-948. PubMed ID: 29322349
[TBL] [Abstract][Full Text] [Related]
8. In situ process analytical technology for real time viable cell density and cell viability during live-virus vaccine production.
Lomont JP; Smith JP
Int J Pharm; 2024 Jan; 649():123630. PubMed ID: 38040394
[TBL] [Abstract][Full Text] [Related]
9. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality.
Yang WC; Lu J; Kwiatkowski C; Yuan H; Kshirsagar R; Ryll T; Huang YM
Biotechnol Prog; 2014; 30(3):616-25. PubMed ID: 24574326
[TBL] [Abstract][Full Text] [Related]
10. Pre-stage perfusion and ultra-high seeding cell density in CHO fed-batch culture: a case study for process intensification guided by systems biotechnology.
Stepper L; Filser FA; Fischer S; Schaub J; Gorr I; Voges R
Bioprocess Biosyst Eng; 2020 Aug; 43(8):1431-1443. PubMed ID: 32266469
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cell culture performance using inducible anti-apoptotic genes E1B-19K and Aven in the production of a monoclonal antibody with Chinese hamster ovary cells.
Figueroa B; Ailor E; Osborne D; Hardwick JM; Reff M; Betenbaugh MJ
Biotechnol Bioeng; 2007 Jul; 97(4):877-92. PubMed ID: 17099908
[TBL] [Abstract][Full Text] [Related]
12. Platform development for high-throughput optimization of perfusion processes-Part II: Variation of perfusion rate strategies in microwell plates.
Dorn M; Lucas C; Klottrup-Rees K; Lee K; Micheletti M
Biotechnol Bioeng; 2024 Jun; 121(6):1774-1788. PubMed ID: 38433473
[TBL] [Abstract][Full Text] [Related]
13. Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study.
Xu J; Xu X; Huang C; Angelo J; Oliveira CL; Xu M; Xu X; Temel D; Ding J; Ghose S; Borys MC; Li ZJ
MAbs; 2020 Jan; 12(1):1770669. PubMed ID: 32425110
[TBL] [Abstract][Full Text] [Related]
14. Small-scale bioreactor supports high density HEK293 cell perfusion culture for the production of recombinant Erythropoietin.
Schwarz H; Zhang Y; Zhan C; Malm M; Field R; Turner R; Sellick C; Varley P; Rockberg J; Chotteau V
J Biotechnol; 2020 Feb; 309():44-52. PubMed ID: 31891733
[TBL] [Abstract][Full Text] [Related]
15. Boosting Productivity for Advanced Biomanufacturing by Re-Using Viable Cells.
Reger LN; Saballus M; Matuszczyk J; Kampmann M; Wijffels RH; Martens DE; Niemann J
Front Bioeng Biotechnol; 2023; 11():1106292. PubMed ID: 36873352
[TBL] [Abstract][Full Text] [Related]
16. The effect of hyperosmolality application time on production, quality, and biopotency of monoclonal antibodies produced in CHO cell fed-batch and perfusion cultures.
Qin J; Wu X; Xia Z; Huang Z; Zhang Y; Wang Y; Fu Q; Zheng C
Appl Microbiol Biotechnol; 2019 Feb; 103(3):1217-1229. PubMed ID: 30554388
[TBL] [Abstract][Full Text] [Related]
17. Principles and approach to developing mammalian cell culture media for high cell density perfusion process leveraging established fed-batch media.
Lin H; Leighty RW; Godfrey S; Wang SB
Biotechnol Prog; 2017 Jul; 33(4):891-901. PubMed ID: 28371394
[TBL] [Abstract][Full Text] [Related]
18. Modulation and modeling of monoclonal antibody N-linked glycosylation in mammalian cell perfusion reactors.
Karst DJ; Scibona E; Serra E; Bielser JM; Souquet J; Stettler M; Broly H; Soos M; Morbidelli M; Villiger TK
Biotechnol Bioeng; 2017 Sep; 114(9):1978-1990. PubMed ID: 28409838
[TBL] [Abstract][Full Text] [Related]
19. Cell-controlled hybrid perfusion fed-batch CHO cell process provides significant productivity improvement over conventional fed-batch cultures.
Hiller GW; Ovalle AM; Gagnon MP; Curran ML; Wang W
Biotechnol Bioeng; 2017 Jul; 114(7):1438-1447. PubMed ID: 28128436
[TBL] [Abstract][Full Text] [Related]
20. Process intensification to produce a difficult-to-express therapeutic enzyme by high cell density perfusion or enhanced fed-batch.
Särnlund S; Jiang Y; Chotteau V
Biotechnol Bioeng; 2021 Sep; 118(9):3533-3544. PubMed ID: 33914903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
